Roche signs potential $1b adc cancer deal with china’s medilink – Artofit

Image gallery for: Roche signs potential $1b adc cancer deal with china’s medilink

Roche Signs Potential $1B ADC Cancer Deal with China’s MediLink

The antibody-drug conjugate market remains hot so far in 2024 with Tuesday’s collaboration and license agreement between Roche and MediLink Therapeutics to develop a next-generation ADC in oncology.
Advertisement
FDA Approves First One-Time Cell Therapy for a Solid Tumor

Michael Deem
With 70% Efficacy, AstraZeneca-Oxford COVID-19 Vaccine Heads to Regulators

A Covid Pandemic
Merck’s Potential $3B EyeBio Acquisition Puts Drugmaker Back in Ophthalmology

Michael Deem
Boehringer Ingelheim Targets Stroma-Rich Cancers in Potential $509M AI Deal

Michael Deem
Advertisement
Roger Guillemin (1924–2024), neuroscientist who showed how the brain controls hormones

Michael Deem
Millions of research papers at risk of disappearing from the Internet

EDUCATION
The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture

Michael Deem
Exclusive: the Trump administration demoted this climate scientist — now she wants reform

People & the Political
Vertex-CRISPR’s Casgevy Gets Positive EMA Panel Opinion, Approval Decision in Q1 2024

Michael Deem
Guidelines for academics aim to lessen ethical pitfalls in generative

Michael Deem
Novo Licenses to Almirall Potential First-in-Class Antibody Candidate

Michael Deem